On May 2, 2025, Unity Biotechnology announced a plan to reduce costs, including a workforce reduction expected to incur about $3.7 million in expenses. This is part of a strategy to preserve capital after revealing results from its ASPIRE study on May 5, 2025, which showed promising data for its drug UBX1325 in treating diabetic macular edema.